Citations

Showing 10 of 108083 citations.

Impact of Genetic Disorders in the Surgical Management of Congenital Heart Disease
Stephens, Elizabeth H. , Dearani, Joseph A. , Connolly, Heidi M. , Gleich, Stephen J. , Deyle, David R. , Johnson, Jonathan N. , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 3, 2023 | Volume: 14 | Issue: 2 | Pages: 201-210

10.1177/21501351221139837 | PMID 36866650 Get It

The congenital heart surgeon frequently encounters patients with various genetic disorders requiring surgical intervention. Although the specifics of the genetics for these patients and their families lie in the purview of specialists in genetics, the surgeon is well-served to be familiar with aspects of specific syndromes that impact surgical management and perioperative care. This aids in counseling families in expectations for the hospital course and recovery as well as can impact intraoperative and surgical management. This review article summarizes key characteristics for the congenital heart surgeon to be familiar with for common genetic disorders as they help coordinate care.
Central Apnea in Patients with COVID-19 Infection
Puram, Vikram , Sethi, Anish , Epstein, Olga, Ghannam, Malik , Brown, Kevin, Ashe, James , Epstein, Olga, Berry, Brent

Mayo Clinic

J | March 3, 2023 | Volume: 6 | Issue: 1 | Pages: 164-171

10.3390/j6010012 Get It

Background: The Coronavirus Disease 2019 (COVID-19) is a global pandemic that has killed over 1.5 million people worldwide. A constellation of multisystem involvement with SARS-CoV-2 has been reported. COVID-19 has been shown to affect the human nervous system, however, both the extent and severity of involvement have yet to be fully elucidated. In this manuscript, we aimed to better understand the effect of COVID-19 on neuro-respiratory status by studying COVID-19 patients who presented with central apnea. Methodology: We analyzed patient characteristics, clinical outcomes, laboratory results, and imaging results of three patients with symptomatic, PCR-proven COVID-19 and episodes of central apnea. Results: Of the three patients included in this study, two patients developed new central apnea, and one patient developed an exacerbation of underlying central apnea despite COVID-19 treatments with systemic steroids and remdesivir. All occurred, on average, 15 days after the onset of COVID-19 symptoms. At 1-year follow-up, all patients experienced complete resolution of apneic breathing. Conclusions: Physicians should be vigilant for the presentation of COVID-19 with central apnea. Central apnea may be a complication in patients with severe COVID-19 infection. More research is warranted to further understand this association.
Hyperlipidaemia elicits an atypical, T helper 1–like CD4+ T-cell response: a key role for very low-density lipoprotein
Os, Bram W. van , Vos, Winnie G. , Bosmans, Laura A. , Lith, Sanne C. , Toom, Myrthe S den, Beckers, Linda, Levels, J.H.M. , Wouw, Suzanne A.E. van , Zaal, Esther A. , Lest, Chris H A van der, Helms, J. Bernd , Weber, Christian , Winther, Menno P.J. de , van Os, Bram W , Weber, Christian , de Winther, Menno P J , Tiel, Claudia M. van , Toom, Myrthe den, Zelcer, Noam , Berkers, Celia R. , Lest, Chris H.A. van de , Atzler, Dorothee , Baardman, Jeroen , Lutgens, Esther

Mayo Clinic

European Heart Journal Open | March 3, 2023 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/ehjopen/oead013 | PMID 36969380 Get It

Abstract Aims Hyperlipidemia and T cell driven inflammation are important drivers of atherosclerosis, the main underlying cause of cardiovascular disease. Here, we detailed the effects of hyperlipidemia on T cells. Methods and results In vitro, exposure of human and murine CD4+ T cells to very low-density lipoprotein (VLDL), but not to low-density lipoprotein (LDL) resulted in upregulation of Th1 associated pathways. VLDL was taken up via a CD36-dependent pathway and resulted in membrane stiffening and a reduction in lipid rafts. To further detail this response in vivo, T cells of mice lacking the LDL receptor (LDLr), which develop a strong increase in VLDL cholesterol and triglyceride levels upon high cholesterol feeding were investigated. CD4+ T cells of hyperlipidemic Ldlr-/- mice exhibited an increased expression of the C-X-C-chemokine receptor 3 (CXCR3) and produced more interferon-γ (IFN-γ). Gene set enrichment analysis identified IFN-γ-mediated signaling as the most upregulated pathway in hyperlipidemic T cells. However, the classical Th1 associated transcription factor profile with strong upregulation of Tbet and Il12rb2 was not observed. Hyperlipidemia did not affect levels of the CD4+ T cell's metabolites involved in glycolysis or other canonical metabolic pathways but enhanced amino acids levels. However, CD4+ T cells of hyperlipidemic mice showed increased cholesterol accumulation and an increased arachidonic acid (AA) to docosahexaenoic acid (DHA) ratio, which was associated with inflammatory T cell activation. Conclusions Hyperlipidemia, and especially its VLDL component induces an atypical Th1 response in CD4+ T cells. Underlying mechanisms include CD36 mediated uptake of VLDL, and an altered AA/DHA ratio.
Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk
Forteza, María J. , Berg, M , Edsfeldt, Andreas , Sun, Jiangming , Kareinen, Ilona , Casagrande, Felipe Beccaria , Zhang, Song , Vučković, Ivan , Dzeja, Petras P. , Trauelsen, Mette , Schwartz, Thue W. , Dib, Lea , Herrmann, Joerg , Monaco, Claudia , Matic, Ljubica , Gonçalves, Isabel , Ketelhuth, Daniel F.J. , Kareinen, Ilona , Hedin, Ulf , Gisterå, Anton , Dib, Lea , Monaco, Claudia , Ketelhuth, Daniel F J , Vuckovic, Ivan , Baumgartner, Roland , Polyzos, Konstantinos A.

Mayo Clinic

Cardiovascular Research | March 3, 2023 | Volume: 119 | Issue: 7 | Pages: 1524-1536

10.1093/cvr/cvad038 | PMID 36866436 Get It

Abstract Aims Recent studies have revealed a close connection between cellular metabolism and the chronic inflammatory process of atherosclerosis. While the link between systemic metabolism and atherosclerosis is well established, the implications of altered metabolism in the artery wall are less understood. Pyruvate dehydrogenase kinase (PDK)-dependent inhibition of pyruvate dehydrogenase (PDH) has been identified as a major metabolic step regulating inflammation. Whether the PDK/PDH axis plays a role in vascular inflammation and atherosclerotic cardiovascular disease remains unclear. Methods and results Gene profiling of human atherosclerotic plaques revealed a strong correlation between PDK1 and PDK4 transcript levels and the expression of pro-inflammatory and destabilizing genes. Remarkably, the PDK1 and PDK4 expression correlated with a more vulnerable plaque phenotype, and PDK1 expression was found to predict future major adverse cardiovascular events. Using the small-molecule PDK inhibitor dichloroacetate (DCA) that restores arterial PDH activity, we demonstrated that the PDK/PDH axis is a major immunometabolic pathway, regulating immune cell polarization, plaque development, and fibrous cap formation in Apoe−/− mice. Surprisingly, we discovered that DCA regulates succinate release and mitigates its GPR91-dependent signals promoting NLRP3 inflammasome activation and IL-1β secretion by macrophages in the plaque. Conclusions We have demonstrated for the first time that the PDK/PDH axis is associated with vascular inflammation in humans and particularly that the PDK1 isozyme is associated with more severe disease and could predict secondary cardiovascular events. Moreover, we demonstrate that targeting the PDK/PDH axis with DCA skews the immune system, inhibits vascular inflammation and atherogenesis, and promotes plaque stability features in Apoe−/− mice. These results point toward a promising treatment to combat atherosclerosis.
Innate and Adaptive Immune Systems in Physiological and Pathological Pregnancy
Weng, Jessica , Couture, Camille , Weng, Jessica , Girard, Sylvie

Mayo Clinic

Biology | March 3, 2023 | Volume: 12 | Issue: 3 | Pages: 402

10.3390/biology12030402 | PMID 36979094 Get It

The dynamic immunological changes occurring throughout pregnancy are well-orchestrated and important for the success of the pregnancy. One of the key immune adaptations is the maternal immune tolerance towards the semi-allogeneic fetus. In this review, we provide a comprehensive overview of what is known about the innate and adaptive immunological changes in pregnancy and the role(s) of specific immune cells during physiological and pathological pregnancy. Alongside this, we provided details of remaining questions and challenges, as well as future perspectives for this growing field of research. Understanding the immunological changes that occur can inform potential strategies on treatments for the optimal health of the neonate and pregnant individual both during and after pregnancy.
The radiologically isolated syndrome: revised diagnostic criteria
Lebrun‐Frénay, Christine , Okuda, Darin T. , Sıva, Aksel , Landes-Château, Cassandre , Azevedo, Christina , Mondot, Lydiane , Louapre, Céline , Durand‐Dubief, Françoise , Page, Emmanuelle Le , Bensa, Caroline , Ciron, Jonathan , Casez, Olivier , Mathey, Guillaume , Zeydan, Burcu , Makhani, Naila , Tütüncü, Melih , Levraut, Michaël , Thouvenot, Éric , Pelletier, Daniel , Kantarci, Orhun H. , Zeydan, Burcu , Lebrun‐Frénay, Christine , Siva, Aksel , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Okuda, Darin T , Mondot, Lydiane , Carra‐Dallière, Clarisse , Zéphir, Hélène , Bensa, Caroline , Ruet, Aurélie , Laplaud, David , Casez, Olivier , Seze, Jerome De , Cohen, Mikaël

Mayo Clinic

Brain | March 3, 2023 | Volume: 146 | Issue: 8 | Pages: 3431-3443

10.1093/brain/awad073 | PMID 36864688 Get It

Abstract The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1–2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.
The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis
Kugelmas, Marcelo , Noureddin, Mazen , Gunn, Nadege , Brown, Kimberly , Younossi, Zobair M. , Alkhouri, Naim , Younossi, Zobair , Abdelmalek, Manal, Abdelmalek, Manal F.

Mayo Clinic

Liver International | March 3, 2023 | Volume: 43 | Issue: 5 | Pages: 964-974

10.1111/liv.15555 | PMID 36864668 Get It

Abstract There is ongoing recognition of the burden of non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH), with fibrosis being the most important histological feature that is associated with progression to cirrhosis and the occurrence of major adverse liver outcomes. Liver biopsy is the gold standard applied to detect NASH and determine the stage of fibrosis, but its use is limited. There is a need for non‐invasive testing (NIT) techniques to identify patients considered at‐risk NASH (NASH with NAFLD activity score > 4 and ≥ F2 fibrosis). For NAFLD‐associated fibrosis, several wet (serological) and dry (imaging) NITs are available and demonstrate a high negative predictive value (NPV) for excluding those with advanced hepatic fibrosis. However, identifying at‐risk NASH is more challenging; there is little guidance on how to use available NITs for these purposes, and these NITs are not specifically designed to identify at‐risk NASH patients. This review discusses the need for NITs in NAFLD and NASH and provides data to support the use of NITs, focusing on newer methods to non‐invasively identify at‐risk NASH patients. This review concludes with an algorithm that serves as an example of how NITs can be integrated into care pathways of patients with suspected NAFLD and potential NASH. This algorithm can be used for staging, risk stratification and the effective transition of patients who may benefit from specialty care.
International society of sports nutrition position stand: energy drinks and energy shots
Kerksick, Chad M. , Gonzalez, Adam M. , Kreider, Richard B. , Arent, Shawn M. , Jäger, Ralf , Smith‐Ryan, Abbie E. , Stout, Jeffrey R. , VanDusseldorp, Trisha A. , Jagim, Andrew R , Harty, Patrick S , Kerksick, Chad M , Kreider, Richard B , Arent, Shawn M , Smith-Ryan, Abbie E , Stout, Jeffrey R , Antonio, Jose , Jagim, Andrew R. , Harty, Patrick S. , Tinsley, Grant M , Campbell, Bill I , António, José

Mayo Clinic

Journal of the International Society of Sports Nutrition | March 2, 2023 | Volume: 20 | Issue: 1 | Pages: No page available

10.1080/15502783.2023.2171314 | PMID 36862943 Get It

Efficacy and safety of Tuina for chronic nonspecific low back pain: A PRISMA-compliant systematic review and meta-analysis
Yang, Juan , Zhou, Xuan , Ma, Qingyu , Woods, Jeffrey , Mohabbat, Arya B. , Do, Alexander , Brault, Jeffrey S. , Jensen, Mark A. , Shin, Kyung-Min , Shen, Longbin , Zhao, Canghuan , Cheong, Philip , He, Kejie , Guo, Yu , Chen, Zhuoming , Tang, Yong , Tan, Celia Ia Choo , Bauer, Brent A. , Woods, Jeffrey T., Tang, Shujie , Chen, Jiaxu

Mayo Clinic

Medicine | March 2, 2023 | Volume: 102 | Issue: 9 | Pages: e33018

10.1097/md.0000000000033018 | PMID 36862888 Get It

Objective: Chronic nonspecific low back pain (CNLBP) is a serious medical and social problem resulting in functional decline and decreased work ability. Tuina, a form of manual therapy, has been sparsely used to treat patients with CNLBP. To systematically assess the efficacy and safety of Tuina for patients with CNLBP. Methods: Multiple English and Chinese literature databases were searched until September 2022 for randomized controlled trials (RCTs) of Tuina in the treatment of CNLBP. The methodological quality was assessed using the Cochrane Collaboration’s tool, and certainty of the evidence was determined with the online Grading of Recommendations, Assessment, Development and Evaluation tool. Results: Fifteen RCTs with 1390 patients were included. Tuina demonstrated a significant effect on pain (SMD: −0.82; 95% CI −1.12 to −0.53; P < .001; I 2 = 81%) and physical function (SMD: −0.91; 95% CI −1.55 to −0.27; P = .005; I 2 = 90%) when compared to control. However, Tuina resulted in no significant improvement for quality of life (QoL) (SMD: 0.58; 95% CI −0.04 to 1.21; P = .07; I 2 = 73%;) compared to control. The Grading of Recommendations, Assessment, Development and Evaluation evidence quality was determined to be low level for pain relief, physical function, and QoL measurements. Only six studies reported adverse events; none were serious. Conclusion: Tuina might be an effective and safe strategy for treating CNLBP in terms of pain and physical function, but not for QoL. The study results should be interpreted with caution for their low-level evidence. More multicenter, large-scale RCTs with a rigorous design are required to further confirm our findings.
Characteristics of patients who return to work after undergoing surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Michalopoulos, Giorgos D. , Shaffrey, Christopher I. , Gottfried, Oren N., Johnson, Eli , Bisson, Erica F. , Wang, Michael Y. , Knightly, John J. , Virk, Michael S., Tumialán, Luis M. , Turner, Jay D. , Upadhyaya, Cheerag D., Shaffrey, Mark E., Park, Paul , Foley, Kevin T. , Coric, Domagoj , Slotkin, Jonathan R., Potts, Eric A. , Chou, Dean , Fu, Kai-Ming, Haid, Regis W., Asher, Anthony L. , Bydon, Mohamad , Mummaneni, Praveen V. , Than, Khoi D. , Michalopoulos, Giorgos , Bergin, Stephen M., Virk, Michael S.

Mayo Clinic

Journal of Neurosurgery: Spine | March 2, 2023 | Volume: 38 | Issue: 5 | Pages: 530-539

10.3171/2023.1.spine221078 | PMID 36805526 Get It

OBJECTIVE Return to work (RTW) is an important surgical outcome for patients who are employed, yet a significant number of patients with cervical spondylotic myelopathy (CSM) who are employed undergo cervical spine surgery and fail to RTW. In this study, the authors investigated factors associated with failure to RTW in the CSM population who underwent cervical spine surgery and who were considered to have a good surgical outcome yet failed to RTW. METHODS This study retrospectively analyzed prospectively collected data from the cervical myelopathy module of a national spine registry, the Quality Outcomes Database. The CSM data set of the Quality Outcomes Database was queried for patients who were employed at the time of surgery and planned to RTW postoperatively. Distinct multivariable logistic regression models were fitted with 3-month RTW as an outcome for the overall population to identify risk factors for failure to RTW. Good outcomes were defined as patients who had no adverse events (readmissions or complications), who had achieved 30% improvement in Neck Disability Index score, and who were satisfied (North American Spine Society satisfaction score of 1 or 2) at 3 months postsurgery. RESULTS Of the 409 patients who underwent surgery, 80% (n = 327) did RTW at 3 months after surgery. At 3 months, 56.9% of patients met the criteria for a good surgical outcome, and patients with a good outcome were more likely to RTW (88.1% vs 69.2%, p < 0.01). Of patients with a good outcome, 11.9% failed to RTW at 3 months. Risk factors for failing to RTW despite a good outcome included preoperative short-term disability or leave status (OR 3.03 [95% CI 1.66–7.90], p = 0.02); a higher baseline Neck Disability Index score (OR 1.41 [95% CI 1.09–1.84], p < 0.01); and higher neck pain score at 3 months postoperatively (OR 0.81 [95% CI 0.66–0.99], p = 0.04). CONCLUSIONS Most patients with CSM who undergo spine surgery reenter the workforce within 3 months from surgery, with RTW rates being higher among patients who experience good outcomes. Among patients with good outcomes who were employed, failure to RTW was associated with being on preoperative short-term disability or leave status prior to surgery as well as higher neck pain scores at baseline and at 3 months postoperatively.